COMMUNIQUÉS West-GlobeNewswire

-
Clene to Present at the Emerging Growth Conference
20/10/2025 -
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
20/10/2025 -
NewGen Announces Strategic Entry into Art Tokenization Market with $2 Million Private Collection Deal, Expandable to $200 Million
20/10/2025 -
PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair
20/10/2025 -
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
20/10/2025 -
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU
20/10/2025 -
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
20/10/2025 -
SARMs RAD 140 (Testolone) and IBUTAMOREN MK-677 SARMS Stack: Crazy Bulk Lunch Rad 140 Effective Sarms for Bulking and Muscle Growth in 2025
20/10/2025 -
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
20/10/2025 -
OneMedNet Welcomes Our Latest Subscriber mlHealth360
20/10/2025 -
AAMI and TechNation Collaborate to Survey HTM Field
20/10/2025 -
Avance Clinical Launches Dedicated Center of Excellence to Accelerate Early Phase Biotech Trials
20/10/2025 -
VitalHub Announces Q3 2025 Conference Call Date
20/10/2025 -
ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
20/10/2025 -
Eleos to Launch Polaris AI Advanced, Purpose-Built Foundational AI Model for Post-Acute Care, built with Google Cloud Technology
20/10/2025 -
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
20/10/2025 -
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET
20/10/2025 -
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
20/10/2025 -
Angelini Ventures Deepens Commitment to CoMind, a Neurotech Redefining Brain Monitoring, with Participation in $60 Million Round Bringing Total Funding to $102.5 Million
20/10/2025
Pages